Oestrogen receptor β: What it means for patients with breast cancer

Valerie Speirs*, Pauline J. Carder, Sally Lane, David Dodwell, Mark R.J. Lansdown, Andrew M. Hanby

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

115 Citations (Scopus)

Abstract

Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

Original languageEnglish
Pages (from-to)174-181
Number of pages8
JournalLancet Oncology
Volume5
Issue number3
DOIs
Publication statusPublished - 1 Mar 2004

Fingerprint

Dive into the research topics of 'Oestrogen receptor β: What it means for patients with breast cancer'. Together they form a unique fingerprint.

Cite this